and everyone. Bob, morning, you, good Thank
be As ivonescimab. Bob our future of accomplished said, can I Summit candidate, remain about incredibly possibilities lead and what enthusiastic of with the the
detail including In our at have would are sponsored our at trials been with featured trials in cancer across bag reviewing XXXX, additional III and oral current Summit, pipeline, biliary presentations Summit publications patients the X like conferences. some and trial providing X alone, head Phase selected X and ] in and of neck, lung are X Phase X,XXX partners studying ivonescimab HARMONi in [ sponsored medical our breast the readout cell triple-negative Currently, Since of III partner, which X types top XXXX, than have and and non-small conducted has Summit treated X Akeso waiting to in are cancers. completed first-line between and some interest Akeso work the Akeso enrollment, trials received entering currently drugs data team with with first are in sponsored these been at major recognition I tract, clinical the of ongoing, X XX trial. line ivonescimab for clinical on year. clinic more tumor ivonescimab ivonescimab. Before touch been was the that last
announced being indications, additional intention start also and to support carcinoma, cancer including a additional epatocellular ovarian significant colorectal more pancreatic study addition cancer, this clinical cancer in has A later data year. lung the generated [ its Akeso cancer, ] in cancer data gastric amount of program. in to is
the squamous HARMONi-X metastatic, as expressing expected tumors cancer cell endpoints, population last XX% to significantly tumors line approximately sponsored to Turning in mutations of completed fourth tumors in quarter, amended to Summit specifically States A expanding patients and data mid-XXXX. top contain lung Bob enrollment progression-free expected this expressing. the in HARMONi overall pipeline, with high is without large represent addressable proportion PD-LX data mentioned non-squamous the non-small low includes negative, both to frontline tumors all with by by in non-small for This patients tumors. driver Squamous the with data and quarter including a include patients survival with patient survival. trial was primary lung reminder, XX% cancer cell non-squamous that PD-LX United rest. of are representing addition the PD-LX to
After plan States. our activate intention to initiate around interest year, HARMONi-X early clinical around United cancer. expanding clinical beyond enrollment to announced we begun our we signals expect XX details in We where in today, the development announce receiving ivonescimab, specifically additional lung to site our which activities opportunity which Echo most this settings XXXX, trial show sponsored yet than Later we for will in not ISTs ] trials more clinical investigator-sponsored XX the to window, either can or in have has had recent over explore. enhance open the [ for approved have
has studied which our now started Anderson, in with enrollment for open that MD collaboration XXXX In and activated are Houston.
to either collaboration additional things discover million We additional outside its activities. biomarkers the through plan several have well committed of possibility ivonescimab as XX the including opportunities as buying current for quickly to development of tumor
Finally, multiple trial collaboration at clinical Pfizer announced ivonescimab several ] this tumor types. in ADCs [ we as with will morning, with in look Pfizer vedotin-based combination our
the [ ivonescimab beyond As with to will across non-small in to trials, ] promising overseas and quickly will ivonescimab part Clinical and as mid-XXXX. collaboration development provider. study. ] the other expected [indiscernible] late-stage join some these our [ advance ivonescimab trials for development we of set associated of responsible cancer be we and are this most collaboration operations innovative combination tumor provide lung evaluate will the us start to accelerate to setting plan allow of seek ADCs costs with Pfizer Tek's
the novel and [ ivonescimab significantly As story, of a has compound. to new of that Summit both together X the clinical into targets development those the highly validated ]. Ivonescimab for PD-X bispecific antibody VGS reminder in [indiscernible] class targets one
I like and upcoming this Next, year would review beyond. catalysts for to
first global potential [ territories, survival for our survival. primary on applying we States. As III ] line we ivonescimab trial endpoints overall including clinical a expect top moment to marketing provides in progression-free which a we be data potentially HARMONi This path will in the expecting authorization are for which United and ago, will both include mid-XXXX of the readout Phase touch
Secondly, expand cancer go sponsor we cell XXXX. to XXXX plan intend lung [indiscernible] beyond in to non-small development our and
a in In tumor rapidly seeking additional increasing And of of conduct of investigators tumor number to a types. investigator-sponsored with addition solid of continual institutions variety number adverse see to engagement activating large continuing a you trial ISTs across different settings. will
cancer execution and of frontline as completing This as including is with small breast study. and cancer [indiscernible] Phase its [ III Phase squamous enrollment Akeso the in well tran-negative in cancer enrollment with of combined addition cancer, so of its tract its ] lung HARMONi-X head ] continuing to neck studies, [ continuing the III ivonescimab biliary cat
readouts in finally, the we see II non-small we of on this III initiations indications times. Over to tumor Phase and which earlier. continue which in cancer expect clinical Akeso lung will in we in year, Akeso from of trial variety Phase data has to generated, data likely beyond touched cell And see been more course from
in catalyst strong are belief excited for potential and lives the path the remains or for better, of consistent. to We patient for the improve convention and switch us ahead ivonescimab
a Now trials, to I moment like take ] to review X HARMONi-X ongoing for study our and Phase III would [ HARMONi-X. global design
include trial, the have combination combination against with for includes without endpoint survival and III pembro with non-squamous randomize, HARMONi-X overall regardless patients in with PD-LX alterations non-small HARMONi-X or progression-free HARMONi-X, results by squamous we cell design chemotherapy study negative ivonescimab line tumors. Here, and activating and This in survival, expressing chemotherapy trial non-squamous global treatment [indiscernible] PD-LX low with as stratified Phase [indiscernible] histology. and for will double-blind, clinical for cancer. lung first including evaluating genomic metastatic patients high, squamous of histologies be expression,
overall survival, the Phase Next, lung be tumors against primary non-squamous first-line we double-blind and treatment ] include patients with as pembro clinical [indiscernible] global survival evaluating III cell monotherapy metastat with for design study endpoints for cancer trial, randomized by HARMONi-X. expression. squamous HARMONi-X histologies. high HARMONi-X non progression-free have is for and [ ivonescimab ultimately the stratified monotherapy small PD-LX
As Phase Europe. our a shares U.S. the to the [indiscernible] last of study year, HARMONi-X tumors reminder, data standard in and immunotherapy with expressing III monotherapy HARMONi-X trials specifically PD-LX care reported consistent high with sponsored Akeso for similarity the but which
for is landscape potential value the blockbuster Turning beyond. drug proposition and is treatment a opportunity a be to lung impact ivonescimab, the positioned here cell platform make has to to Ivonescimab the the of well non-small cancer market clear. significant across and
or others alone in [ Specifically studies third TD market checkpoint lung of a combined approach start. just ultimately announced the a or this cancer billion there cell addressable can could but conducted the from lung Summit. according ongoing Akeso inhibitors Non-small to an by that quarter cell $XX and either likes for are ] Phase non-small III cancer, has research is X
of to be have developed beyond tested approved. non-small are ] VGTs PD-X, Across indications rapidly than will [indiscernible] all or research. where PD-LX inhibitors market $XX to There Ivonescimab according continue billion next indications, in couple the cell addressable the and cancer. approached lung been globally [ XX more checkpoint years,
lung cancer, effective, this full tumor excludes microsatellite could have cancer in colorectal have, therapy. negative where after impact data not cancer that shown the still [indiscernible], and low EGFR PD-LX stable cell However, including it non-small targeted multiple been promising mutant breast where has ivonescimab inhibitors checkpoint
our We continue development excited in lung [ to cancer are progress 'XX. ] into to small
facing lung of goal showed There at Additionally, III that standard data potential multiple cancer solid encouraging to current opportunity ] data the ongoing we global lives ivonescimab noosed Summit. a trials intend Phase shared care have continue a to explore are has than high continue that the become and of providing studies in tumor and that much to possible which ivonescimab we needs. clinical medical XXXX several are Phase to explore many improve as across unmet to conducted, as with to our patients market sponsoring settings, a II been larger [
partner patients opportunity our would importantly, like collaborators Anderson clinical at our to to in the hospitals, our thank I ivonescimab MD globally. Shaw entire take the team, in as our most Summit including China, Dr. of continue rapid studies Michel also course, well and investigators, to Akeso development as the the ] and way team. the pave as And [ we for of
on past done years, I a a over where time X our all across and condensing As ] of [ parent possible. Summit many just back making look achievements has the Bob when tremendous and appropriately goals Team job every in reality and the
would each cancer therapeutic I It our of in to everyone to needs. time is to continue our at look my privilege work thanks Summit, high and with opportunities Team unmet to bringing additional line like and honor [indiscernible] We with to an members. of express team accelerate member options patients to
I and will Manmeet details provide position operations now financial update, on that update. ask our With
